Klingman & Associates LLC Trims Holdings in Stryker Co. (NYSE:SYK)

Klingman & Associates LLC decreased its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 24.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 2,790 shares of the medical technology company's stock after selling 910 shares during the period. Klingman & Associates LLC's holdings in Stryker were worth $1,005,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of SYK. Whittier Trust Co. raised its position in Stryker by 24.0% during the third quarter. Whittier Trust Co. now owns 4,150 shares of the medical technology company's stock worth $1,499,000 after acquiring an additional 804 shares in the last quarter. Foundations Investment Advisors LLC grew its stake in Stryker by 10.0% during the third quarter. Foundations Investment Advisors LLC now owns 1,753 shares of the medical technology company's stock worth $633,000 after buying an additional 160 shares in the last quarter. Sky Investment Group LLC raised its position in Stryker by 3.7% during the third quarter. Sky Investment Group LLC now owns 15,119 shares of the medical technology company's stock valued at $5,462,000 after purchasing an additional 533 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in Stryker by 1.7% in the third quarter. Sequoia Financial Advisors LLC now owns 11,236 shares of the medical technology company's stock valued at $4,059,000 after acquiring an additional 187 shares during the last quarter. Finally, Eastern Bank increased its position in Stryker by 313.5% during the 3rd quarter. Eastern Bank now owns 3,730 shares of the medical technology company's stock worth $1,347,000 after purchasing an additional 2,828 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the company's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $442.00 target price on shares of Stryker in a research report on Wednesday, January 29th. Morgan Stanley upgraded Stryker from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Royal Bank of Canada raised their price target on shares of Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. The Goldman Sachs Group raised their price target on shares of Stryker from $384.00 to $427.00 and gave the company a "neutral" rating in a research report on Thursday, January 30th. Finally, StockNews.com lowered Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $420.68.

Stryker Trading Down 1.0 %

Stryker stock traded down $3.82 during mid-day trading on Friday, hitting $382.59. The company's stock had a trading volume of 1,268,413 shares, compared to its average volume of 1,388,856. The business has a 50 day moving average price of $377.92 and a 200-day moving average price of $368.21. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The stock has a market cap of $145.99 billion, a price-to-earnings ratio of 49.30, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the firm posted $3.46 earnings per share. As a group, analysts forecast that Stryker Co. will post 13.49 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. The ex-dividend date is Monday, March 31st. Stryker's payout ratio is 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.